D. Salazar

发表

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

K. Winters, J. Jakubowski, J. Brandt, 2008, Thrombosis and Haemostasis.

Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed‐Dose Combination

M. Bathala, M. Shenouda, S. Rohatagi, 2008, Journal of clinical pharmacology.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

S. Connolly, J. Weitz, H. Kastrissios, 2010, Thrombosis and Haemostasis.

Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.

N. Alpert, A. Fischman, B. Christian, 1996, The Journal of pharmacology and experimental therapeutics.

Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.

J. Moberly, H. Kastrissios, S. Rohatagi, 2008, British journal of clinical pharmacology.

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation

D. Abernethy, N. Ford, J. Barbey, 2001, Clinical pharmacology and therapeutics.

Chapter 41 – Modern Drug Discovery and Development

D. Salazar, G. Gormley, 2017 .

Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.

P. Kroboth, R. Dockens, D. Salazar, 1995, Journal of clinical psychopharmacology.

Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing

N. Cutler, N. Ford, J. Sramek, 1998, Headache.

A Double-Blind, Randomized, Crossover Assessment of Blood Pressure Following Administration of Avitriptan, Sumatriptan, Or Placebo To Patients with Mild To Moderate Hypertension

N. Cutler, N. Ford, J. Sramek, 1999, Cephalalgia : an international journal of headache.

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

E. Antman, E. Braunwald, S. Wiviott, 2009, Journal of clinical pharmacology.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

R. Kelly, K. Winters, P. Kothare, 2010, Clinical therapeutics.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

K. Winters, P. Kothare, J. Jakubowski, 2010, European Journal of Clinical Pharmacology.

Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

K. Winters, S. Rohatagi, D. Small, 2010, Journal of clinical pharmacology.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

L. Wallentin, K. Winters, C. Ernest, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Effect of Repeated Oral Administrations of the Oral Adsorbent AST-120 on Serum Creatinine and Other Markers of Renal Function

J. Marier, R. Vargas, J. Moberly, 2006, American Journal of Nephrology.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease

K. Winters, R. Wrishko, J. Brandt, 2009, Journal of clinical pharmacy and therapeutics.

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

K. Winters, C. Ernest, J. Jakubowski, 2008, Pharmacotherapy.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

K. Winters, C. Ernest, N. Farid, 2009, Journal of clinical pharmacy and therapeutics.

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

Junxiang Luo, C. Ernest, R. Wrishko, 2012, Journal of clinical pharmacology.

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

E. Antman, S. Wiviott, C. Ernest, 2008 .

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

K. Winters, C. Ernest, N. Farid, 2008, Journal of clinical pharmacology.

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing

K. Winters, C. Ernest, R. Wrishko, 2009, Drugs & aging.

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

K. Winters, J. Jakubowski, J. Brandt, 2008, Platelets.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

K. Winters, C. Ernest, J. Jakubowski, 2009, Current medical research and opinion.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

E. Antman, R. Giugliano, S. Zhou, 2012, Thrombosis and Haemostasis.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

K. Winters, J. Jakubowski, J. Brandt, 2007, Thrombosis and Haemostasis.

Early inhibition of the Na+/K+-ATPase ion pump during acetaminophen-induced hepatotoxicity in rat.

D. Salazar, S. Chung, G. Corcoran, 1987, Biochemical and biophysical research communications.

Induction of cytochrome P450IIE1 in the obese overfed rat.

C. Lieber, J. Kraner, J. Lasker, 1991, Molecular pharmacology.

Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener.

V. Gribkoff, J. Starrett, D. Kiesewetter, 2002, Nuclear medicine and biology.

Obesity as a risk factor in drug-induced organ injury. III. Increased liver and kidney injury by furosemide in the obese overfed rat.

D. Salazar, G. Corcoran, H. Chan, 1989, Toxicology and applied pharmacology.

Obesity decreases hepatic glutathione concentrations and markedly potentiates allyl alcohol-induced periportal necrosis in the overfed rat.

S. W. Jordan, D. Salazar, G. Corcoran, 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

H. Kastrissios, S. Rohatagi, J. Mendell, 2012, Thrombosis and haemostasis.

Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass.

D. Salazar, G. Corcoran, Daniel E. Salazar, 1988, The American journal of medicine.

Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat.

D. Salazar, G. Corcoran, 1989, The Journal of pharmacology and experimental therapeutics.

Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat.

D. Salazar, G. Corcoran, C. Sorge, 1988, Biochemical and biophysical research communications.

Model‐Supported Development of CS‐8635: A Fixed‐Dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Raymond Miller, Helen Moore, S. Rohatagi, 2013, Clinical pharmacology in drug development.

Central Nervous System Pharmacokinetics of Psychiatric Drugs

A. Fischman, D. Salazar, 1999, Journal of clinical pharmacology.

Pharmacokinetic and Pharmacodynamic Evaluation During Coadministration of Nefazodone and Propranolol in Healthy Men

P. Marathe, D. Salazar, R. Raymond, 1995, Journal of clinical pharmacology.

The Effect of AST‐120 on the Single‐Dose Pharmacokinetics of Losartan and Losartan Acid (E‐3174) in Healthy Subjects

R. Guilbaud, J. Marier, J. Moberly, 2006, Journal of clinical pharmacology.

A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects

D. Shindler, J. Seibold, D. Salazar, 1997, Journal of clinical pharmacology.

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.

R. Kauffman, F. Sallee, R. Findling, 2009, Journal of child and adolescent psychopharmacology.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

E. Antman, R. Giugliano, E. Braunwald, 2010, American heart journal.

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

K. Winters, G. Weerakkody, J. Brandt, 2008, Journal of clinical pharmacology.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

S. Iturria, K. Winters, C. Ernest, 2007, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine

J. Macher, L. Citrome, D. Boulton, 2007, Journal of clinical psychopharmacology.

Brasofensine Treatment for Parkinson's Disease in Combination with Levodopa/Carbidopa

J. Webster, N. Cutler, T. Shiovitz, 2002, The Annals of pharmacotherapy.

Pharmacokinetic characteristics of the obese overfed rat.

D. Salazar, G. Corcoran, C. Sorge, 1989, International Journal of Obesity.

Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

D. Salazar, J. Kisicki, K. Brown, 2010, Journal of clinical pharmacology.

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

K. Winters, C. Ernest, J. Jakubowski, 2007, Clinical pharmacology and therapeutics.

Modern Drug Discovery and Development

John C. Alexander, Daniel E. Salazar, D. Salazar, 2009 .

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

K. Winters, C. Ernest, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel

K. Winters, J. Jakubowski, N. Farid, 2010, Clinical pharmacokinetics.

Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension

D. Blowey, J. Blumer, J. Sullivan, 2012, Pediatric Drugs.

Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.

D. Blowey, J. Blumer, J. Sullivan, 2012, Paediatric drugs.

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects

D. R. Wada, S. Rohatagi, D. Salazar, 2012, Clinical pharmacology and therapeutics.

Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers

D. Salazar, S. Mallikaarjun, S. Bramer, 2004, Journal of clinical pharmacology.

Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics

Daniel E. Salazar, William J. Jusko, W. Jusko, 1991, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate

L. Citrome, R. Josiassen, D. Salazar, 2005, Journal of clinical pharmacology.

Pharmacokinetic and Pharmacodynamic Evaluation of Warfarin and Nefazodone Coadministration in Healthy Subjects

P. Chaikin, R. Dockens, D. Salazar, 1995, Journal of clinical pharmacology.

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.

D E Salazar, P. Kroboth, R. Dockens, 1995, Journal of clinical psychopharmacology.

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

P. Rosenfeld, C. Awh, J. Heier, 2020, British Journal of Ophthalmology.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

K. Winters, N. Farid, Y. Li, 2008, Current medical research and opinion.

Absorption and Presystemic Metabolism of Nefazodone Administered at Different Regions in the Gastrointestinal Tract of Humans

P. Marathe, D. Salazar, R. Barbhaiya, 1995, Pharmaceutical Research.

Development of a Predictive Pharmacokinetic Model for a Novel Cyclooxygenase‐2 Inhibitor

J. Moberly, H. Kastrissios, S. Rohatagi, 2006, Journal of clinical pharmacology.

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.

M. Folan, P. Kroboth, R. Lush, 1995, Journal of clinical psychopharmacology.

Evaluation of Population Pharmacokinetics and Exposure‐Response Relationship With Coadministration of Amlodipine Besylate and Olmesartan Medoxomil

S. Rohatagi, D. Salazar, James Lee, 2008, Journal of clinical pharmacology.

PHARMACOKINETICS AND DISPOSITION

D. Salazar, J. Cosson, C. Laroudie, 1999 .

Model‐Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs

Jin Y. Jin, W. Jusko, S. Rohatagi, 2008, Journal of clinical pharmacology.

Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range

R. Croop, R. Dockens, D. Salazar, 2006, Journal of clinical pharmacology.

E. Antman, R. Giugliano, E. Braunwald, 2010, American heart journal.

Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX‐2 Inhibitor

K. Yoshihara, J. Moberly, H. Kastrissios, 2007, Journal of clinical pharmacology.

An open‐label study on the pharmacokinetics (PK) of pitavastatin (NK‐104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers

T. Cuddy, D. Salazar, P. Mathew, 2004 .